Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (261-270 of 740) with videos related to

Pageof 74
Sort By:
Future Oncology (London, England)|September 15, 2021
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM studyPaul G Richardson, Simon J Harrison, Sara Bringhen, et al.
Hemasphere|July 11, 2022
Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy IndividualsIoannis Ntanasis-Stathopoulos, Vangelis Karalis, Aimilia D Sklirou, et al.
Therapeutic Advances in Hematology|April 8, 2022
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairmentMeletios A Dimopoulos, Joseph Mikhael, Evangelos Terpos, et al.
Radiology|September 10, 2016
Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple MyelomaVassilis Koutoulidis, Sophia Fontara, Evangelos Terpos, et al.
Haematologica|December 18, 2012
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trialMeletios A Dimopoulos, Michel Delforge, Roman Hájek, et al.
American Journal of Hematology|June 13, 2013
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimensTina Bagratuni, Efstathios Kastritis, Marianna Politou, et al.
Journal of Clinical Medicine|September 28, 2021
Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-AnalysesRebecca Georgakopoulou, Oraianthi Fiste, Theodoros N Sergentanis, et al.
Haematologica|May 30, 2013
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myelomaMeletios A Dimopoulos, Meral Beksac, Lotfi Benboubker, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 29, 2019
Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variantKonstantinos Liapis, Panagiota Panagopoulou, Evangelia Charitaki, et al.
Leukemia & Lymphoma|June 13, 2017
Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapyEfstathios Kastritis, Pelagia Melea, Tina Bagratuni, et al.
Pageof 74

Showing results (261-270 of 740) with videos related to

Sort By:
Pageof 74
Future Oncology (London, England)|September 15, 2021
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM studyPaul G Richardson, Simon J Harrison, Sara Bringhen, et al.
Hemasphere|July 11, 2022
Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy IndividualsIoannis Ntanasis-Stathopoulos, Vangelis Karalis, Aimilia D Sklirou, et al.
Therapeutic Advances in Hematology|April 8, 2022
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairmentMeletios A Dimopoulos, Joseph Mikhael, Evangelos Terpos, et al.
Radiology|September 10, 2016
Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple MyelomaVassilis Koutoulidis, Sophia Fontara, Evangelos Terpos, et al.
Haematologica|December 18, 2012
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trialMeletios A Dimopoulos, Michel Delforge, Roman Hájek, et al.
American Journal of Hematology|June 13, 2013
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimensTina Bagratuni, Efstathios Kastritis, Marianna Politou, et al.
Journal of Clinical Medicine|September 28, 2021
Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-AnalysesRebecca Georgakopoulou, Oraianthi Fiste, Theodoros N Sergentanis, et al.
Haematologica|May 30, 2013
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myelomaMeletios A Dimopoulos, Meral Beksac, Lotfi Benboubker, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 29, 2019
Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variantKonstantinos Liapis, Panagiota Panagopoulou, Evangelia Charitaki, et al.
Leukemia & Lymphoma|June 13, 2017
Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapyEfstathios Kastritis, Pelagia Melea, Tina Bagratuni, et al.
Pageof 74